PRESS RELEASE

03.21.2019

Epic Sciences to Present New Data at AACR 2019 Demonstrating Expansion of Functional Cell Profiling Technology into New Indications including Breast, Lung and Prostate Cancer

LinkedIn
Twitter
Follow by Email

SAN DIEGO  March 21, 2019 – Epic Sciences, Inc. announced today that new data will be presented at the American Association of Cancer Research (AACR) Annual Meeting 2019, in Atlanta, Georgia, March 29 to April 4, 2019. The data from multiple studies and indications demonstrate the feasibility of Epic’s Functional Cell Profiling (FCP) technology to predict patients’ response to cancer immunotherapies and drugs that target DNA damage repair pathways.

Epic’s FCP technology platform identifies and characterizes all circulating tumor cells in a blood sample to link their response or resistance to several drug classes. Following the highly successful development of Epic’s proprietary AR-V7 test for patients with metastatic castration-resistant prostate cancer, currently marketed as the Oncotype DX AR-V7 Nucleus Detect™ test, the company and its research partners are utilizing the FCP platform to analyze biomarkers to guide treatment decisions in breast cancer and small-cell lung cancer, expanding into new areas of unmet need.

“For years, Epic Sciences has been transforming late-stage prostate cancer treatment with our powerfully predictive Functional Cell Profiling technology by providing a comprehensive view of how populations of cancer cells change under selective pressure of different drug classes,” said Katherine Atkinson, Chief Commercial Officer at Epic Sciences. “At AACR, we are presenting new data that demonstrates our technology’s significant value can be applied to new indications and drug classes in development, in addition to late stage prostate cancer, potentially improving the lives of many more patients.”

Following are the AACR 2019 posters and presentations:

Oral Presentation:

Title:  Liquid Biopsies: From Validation to Clinical Utility

Session Description: Discussion of the development and clinical application of validated circulating tumor cell (CTC) and cell-free DNA assays to determine prognosis, predict response to treatment, identify mechanisms of resistance to guide future treatment, and assess drug effects.

Chairperson & Presentation: Howard I. Scher, Memorial Sloan Kettering Cancer CenterPredictive biomarkers in circulating tumor cells to direct management of metastatic castration-resistant prostate cancer (mCRPC)

Session Date and Time:  April 1, 2019, 2:05 pm – 2:30 pm ET

Poster Presentations:

Title: HER2, AR protein expression and chromosomal instability in circulating tumor cells (CTCs) of metastatic breast cancer (MBC) patients (pts)

Session Category and Title: Clinical Research: Current Developments in Non-invasive Biomarkers for Assessment of Cancer 1

Session Date and Time: Sunday, March 31, 2019 1:00 pm – 5:00 pm ET

Title: Genomic instability as a marker of poor prognosis in advanced prostate cancer: Subclonal insights from whole-genome sequencing of single circulating tumor cells

Session Category and Title: Clinical Research: Current Developments in Non-invasive Biomarkers for Assessment of Cancer 1

Session Date and Time: Sunday,March 31, 2019, 1:00 pm – 5:00 pm ET

Title: Characterization of SLFN11 protein expression in circulating tumor cells (CTCs) of patients with metastatic castration-resistant prostate cancer (mCRPC) prior to platinum based chemotherapy

Session Category and Title: Clinical Research: Circulating and Cell-free Biomarkers for Diagnosis and Monitoring of Cancer 2

Session Date and Time: Monday, April 1, 2019, 8:00 am – 12:00 pm ET

Title: Comparison of the Epic CTC HRD assay vs. tumor DDR mutations in metastatic castration-resistant prostate cancer (mCRPC) patients (pts)

Session Category and Title: Clinical Research: Circulating and Cell-free Biomarkers for Diagnosis and Monitoring of Cancer 3

Session Date and Time: Monday, April 1, 2019, 1:00 pm – 5:00 pm ET

Title: SLFN11 and EZH2 protein expression and localization in circulating tumor cells to predict response or resistance to DNA damaging therapies in small cell lung cancer

Session Category and Title: Circulating and Cell-free Biomarkers for Diagnosis and Monitoring of Cancer 3

Session Date and Time: Monday, April 1, 2019, 1:00 pm – 5:00 pm ET

Title: Single-cell analyses reveal increasing intratumoral heterogeneity as an essential component of treatment resistance in small-cell lung cancer

Session Category and Title: Tumor Biology: Tumor Evolution and Heterogeneity 1

Session Date and Time: Tuesday, April 2, 2019 8:00 am – 12:00 pm ET

Title: Evaluation of pharmacokinetics of proxalutamide, a novel androgen receptor antagonist, in treatment for mCRPC patients via CTC enumeration and AR biomarker analysis

Session Category and Title: Experimental and Molecular Therapeutics: Pharmacokinetics and Pharmacodynamics/Preclinical Toxicology

Session Date and Time: Tuesday, April 2, 2019, 1:00 pm – 5:00 pm ET

Title: Simultaneous quantification of activated immune cells and PD-L1 expressing circulating tumor cells (CTCs) in peripheral blood of cancer patients receiving checkpoint inhibitor therapy

Session Category and Title: Immunology: Biomarkers and Immune Monitoring

Session Date and Time: Tuesday, April 2, 2019, 1:00 pm – 5:00 pm ET

About Epic Sciences, Inc.
Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic Sciences’ mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient’s journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells. Epic Sciences’ No Cell Left Behind® technology helps match patients to therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Epic Sciences has partnered with Genomic Health to commercialize the Oncotype DX AR-V7 Nucleus Detect test, which helps with therapeutic decisions between taxane chemotherapy or androgen-directed therapeutics in metastatic castration-resistant prostate cancer. Today, we partner with leading pharmaceutical companies and major cancer centers around the world. Epic Sciences’ goal is to increase

the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians real-time information to guide treatment choices. Epic Sciences is headquartered in San Diego. Further information is available on the company’s website, www.epicsciences.com. Stay in touch on LinkedIn or on Twitter @EpicSciences.

Media Contacts: Jennifer Guzman, Epic Sciences, 858-216-2217, jennifer.guzman@epicsciences.com

Cammy Duong, Canale Communications, 619-849-5389, cammy@canalecomm.com